Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a Stress-Relieving herb boost your skin and hair?

NCT ID NCT07215689

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a daily 300 mg capsule of KSM-66 Ashwagandha, an herbal supplement, can improve skin and hair health in 50 healthy adults over 12 weeks. Participants are randomly assigned to receive either the supplement or a placebo, and neither they nor the researchers know who gets what. The goal is to see if reducing stress with ashwagandha leads to measurable improvements in skin moisture and hair density.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
KSM-66 Ashwagandha (ashwagandha root extract) dietary supplement
What this could lead to
If it works, this could provide a natural option to improve skin and hair health by reducing stress-related damage.
What could go wrong
This is a small, early-stage trial with only 50 healthy people. Results may not apply to everyone, and supplements are not regulated like drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Healthy adult men and women participants ≥ 18 years and ≤60 years of age. 2. Willingness to follow the protocol requirements as evidenced by written informed consent. 3. Participants who were on consistent dietary, hair, and skin product 3 months prior to start of the study and are willing to follow the same during the study. 4. Participants who agree not to use any medication (prescription and over the counter), including vitamins and minerals, during or before the course of this study. 5. Participants with mild to moderate hair loss classified as the Norwood-Hamilton type II, III, IV and V in males and Ludwig type I and II in females. 6. Willing to come for all follow-up visits. 7. Participants who agree not to cut hair for the entire duration of the study. 8. Participants willing to undergo Trichoscan evaluation and not to wash their hair 48 hours before the visit. 9. Participants or LAR can and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements. 10. Participants who agree to take investigational product (i.e., Till Day 90 ± 4 ± 4). Exclusion Criteria: 1. Participants having any clinically significant medical history, medical finding including rosacea, eczema, psoriasis, and atopic dermatitis or an on-going medical or psychiatric condition exists which in the opinion of the Investigator could jeopardize the safety of the subject, impact validity of the study results or interfere with the completion of study according to the protocol. 2. Participants on any medication or supplement for hair loss, including finasteride, any other 5 α-reductase inhibitor, minoxidil, steroids, or hormonal products, during the 3 months prior to study commencement. 3. Participants having a history of hypersensitivity reactions (i.e., allergic or oversensitivity to study medication). 4. Participants who have undergone or plan to undergo hair transplantation surgery during the study period. 5. Participants with facial skin cancer. 6. Participants with sunburn, moderate to pronounced suntan, uneven skin tones, tattoos, scars or other disfiguration, dilated vessels or other conditions on the test area that might influence the test results. 7. Participants with severe seborrheic dermatitis, alopecic disease, except for androgenic alopecia, and scalp disorders, such as scalp psoriasis and infection. 8. Participants who have participated in a clinical study during the preceding 180 days. 9. Participants having eating disorders (i.e., bulimia, psychogenic eating disorders, etc.). 10. Pregnant and lactating females 11. Participants with alcohol addiction or persistent abuse of drugs of dependence.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • San Francisco Research Institute

    RECRUITING

    San Francisco, California, 94132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.